Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Astellas_Pharma
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Glenn_P._Sblendorio
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
therapies for age-related macular degeneration
|
| gptkbp:focusesOn |
ophthalmology
treatments for eye diseases |
| gptkbp:foundedYear |
2007
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ophthotech Corporation
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Fovista
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:renamed |
gptkb:IVERIC_bio
|
| gptkbp:status |
gptkb:public_company
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:OPHT
|
| gptkbp:website |
www.ophthotech.com
|
| gptkbp:bfsParent |
gptkb:Iveric_Bio
|
| gptkbp:bfsLayer |
6
|